Breast cancer (first line) - bevacizumab

Bevacizumab in combination with non-taxane chemotherapy for the first line treatment of metastatic breast cancer

Status:	In progress
Expected date of issue:	TBC
Referral date:	November 2008
Wave:	19
Process:	STA
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	TBC
Technical Lead:	TBC
Communications manager:	TBC
Project manager:	Phil Higham

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Top

 

Consultees and Commentators

To be confirmed

Top

 

Project history

Date Update 2 July 2009 This appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during early October 2009. The deadline for submissions is expected in approximately mid December 2009 11 November 2009 This appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during late April 2010. The deadline for submissions is expected in approximately early July 2010.

Top

 

Key documents

Breast cancer (first line) - bevacizumab: draft scope 11 February 2010 Breast cancer (first line) - bevacizumab: provisional matrix 11 February 2010

This page was last updated:   02 July 2009